Difference between revisions of "Raltitrexed (Tomudex)"
m (Text replacement - "[[File:" to "[[:File:") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Mesothelioma medications" to "Category:Malignant pleural mesothelioma medications") |
||
| Line 28: | Line 28: | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
| − | [[Category: | + | [[Category:Malignant pleural mesothelioma medications]] |
[[Category:EMA approved drugs]] | [[Category:EMA approved drugs]] | ||
[[Category:Health Canada approved drugs]] | [[Category:Health Canada approved drugs]] | ||
Revision as of 16:42, 1 May 2022
General information
Class/mechanism: Antimetabolite, inhibitor of thymidylate synthase. Raltitrexed is a quinazoline folate analogue which inhibits thymidylate synthase (TS). TSis an enzyme involved in the synthesis of thymidine triphosphate (TTP), a nucleotide required exclusively for DNA synthesis. Inhibiting TS causes DNA damage and cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
No information available.
Diseases for which it is used
Not FDA approved.
Also known as
- Code names: TDX, ZD 1694
- Generic name: raltitrexed disodium
- Brand name: Tomudex